SIETES :: 92822 citas

Resultados de la búsqueda por ANFETAMINA REFINAR BÚSQUEDA

1.

Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]

2.

Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D spending on single-enantiomer drugs versus their racemic precursors . Ann Intern Med 2019:13 de agosto. [Ref.ID 103162]

3.

Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]

4.

Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]

5.

Cortese A, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018:7 de agosto. [Ref.ID 102788]

6.

Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016. Morbidity and Mortality Weekly Report 2018;67:30 de marzo. [Ref.ID 102488]

7.

Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernández-Díaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2017:13 de diciembre. [Ref.ID 102188]

8.

Anónimo. Pitolisant for narcolepsy. Drug Ther Bull 2017;55:6-8. [Ref.ID 101353]

9.

Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet 2016;387:2226-34. [Ref.ID 100335]

10.

Chan E, Fogler JM, Hammemess PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA 2016;315:1997-2008. [Ref.ID 100290]

11.

12.

Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics 2015;136:1144-53. [Ref.ID 99685]

13.

Kaplan J, Shah P, Faley B, Siegel ME. Case reports of aripiprazole causing false-positive urine amphetamine drug screens in children. Pediatrics 2015;136:e1625-1628. [Ref.ID 99579]

14.

Chinthapalli K. The billion dollar business of being smart. BMJ 2015;351:h4829. [Ref.ID 99542]

15.

Cunill R, Castells X. Trastorno por déficit de atención con hiperactividad. Med Clin (Barc) 2015;144:370-5. [Ref.ID 98996]

16.

Anónimo. Lisdexamfetamine /Vyvanse) for binge eating disorder. Med Lett Drugs Ther 2015;57:42. [Ref.ID 98884]

17.

Anónimo. Drugs for ADHD. Med Lett Drugs Ther 2015;57:37-40. [Ref.ID 98882]

18.

Anónimo. FDA expands uses of Vyvanse to treat binge-eating disorder. U.S. Food and Drug Administration 2015:30 de enero. [Ref.ID 98748]

19.

Chen Q, Sjölander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014;348:g3769. [Ref.ID 98058]

20.

Anónimo. Drugs and driving: blood concentration limits to be set for certain controlled drugs in a new legal offence. Drug Safety Update 2014;7:A1. [Ref.ID 97865]